Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Atorvastatin shown to decrease heart disease and stroke


Atorvastatin shown to decrease heart disease and stroke in patients with hypertension and low cholesterol

A major European trial studying different blood pressure treatments and the effects of additional cholesterol lowering, announces today that it has stopped part of its trial earlier than expected because results collected already show a significant benefit to patients on one of its treatments.

It found that among 10,297 patients with hypertension and cholesterol levels lower than currently recommended for treatment, those given the cholesterol-lowering drug atorvastatin suffered significantly less heart attacks and strokes compared to those receiving the placebo treatment.

The International Steering Committee of the independent Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) have stopped the relevant part of the trial and informed fellow investigators, their patients and the regulatory authorities about the newly emerged results.

The rest of the trial, which compares different blood pressure treatment strategies, will continue unchanged.

"The trial shows that patients with high blood pressure but low cholesterol benefit clearly from taking a statin. It is too early to quantify the precise size of the effect, but we expect to see a reduction in heart attacks of about one-third among those taking a statin," say ASCOT study co-chairmen Björn Dahlöf from the Sahlgrenska University Hospital, Östra, Sweden and Peter Sever from Imperial College London, UK.

"However the ASCOT trial still continues and we wish to make it clear to all our patients that this new information does not mean they should stop the tablets they are taking. It is vital that all patients on the trial carry on with their treatment regimens," they add.

All patients will be recalled to visit their ASCOT doctors and will be examined again in the coming weeks

Members of ASCOT’s Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported their findings to the ASCOT International Steering Committee on 2 September 2002.

They described a highly significant reduction in the number of heart attacks and a significant reduction in the number of strokes experienced by those patients receiving atorvastatin compared to placebo.

As the size of the benefit exceeded the stopping rules for this part of the trial, the Data Safety Monitoring Board’s recommendations to close this section of the study were accepted by the ASCOT Steering Committee. This part of the study was formally closed on 1 October 2002 but data collection relating to it is expected to continue until the end of December 2002.

Further announcements about the results of the atorvastatin part of the trial will be made in 2003, with final results of the whole ASCOT study expected in 2004.

Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with low cholesterol levels.

The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.

The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.

By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,297 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.

Patients in the trial are aged between 40 and 79 years old, with high blood pressure and have at least three other pre-specified cardiovascular risk factors.

The primary endpoint of the trial is either a heart attack from which the patient survives or death from coronary heart disease. A large number of other cardiovascular events including stroke are identified as secondary endpoints in the study.


Tony Stephenson | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

nachricht Breakthrough in Mapping Nicotine Addiction Could Help Researchers Improve Treatment
04.10.2016 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Innovative technique for shaping light could solve bandwidth crunch

20.10.2016 | Physics and Astronomy

Finding the lightest superdeformed triaxial atomic nucleus

20.10.2016 | Physics and Astronomy

NASA's MAVEN mission observes ups and downs of water escape from Mars

20.10.2016 | Physics and Astronomy

More VideoLinks >>>